Phathom Pharmaceuticals, Inc. (PHAT): Depreciation & Amortization
$633.0K
Year ended 2025-12-31
$508.0K
Trailing 12 months to 2026-06-30
+0.7%
3-year compound annual growth
+14.4%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $633.0K | -20.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $795.0K | +38.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $575.0K | -7.3% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $620.0K | +19.0% | 2024-06-14, From 2022-01-01 |
| 2021-12-31 | $521.0K | +61.3% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $323.0K | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $8.0K | n/a | 2021-03-30, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $633.0K | -20.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $27.71M | -9.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $2.77M | -12.1% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $500.0K | -28.6% |
| Liquidia Corp (LQDA) | 2025-12-31 | $1.53M | -30.5% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $7.17M | -4.9% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $1.07M | -12.6% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $2.70M | +13.1% |
Compare PHAT, CYRX, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗